FGFR2 and cholangiocarcinoma: This agent demonstrated encouraging clinical activity in a first-in-human study involving 35 patients with FGFR2-altered CCA, with >10% tumor shrinkage observed in 56% of patients with CCA previously treated with an FGFR inhibitor [39,145,147].